GSTM1 and kidney disorder: The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines suggest that ESA therapy should be started when Hb is between 90 and 100 g/L for adult dialysis patients and that ESAs should not be used to maintain an Hb concentration >115 g/L in adult patients with CKD, but that individualization of therapy will be necessary as some patients may have improvements in quality of life at an Hb concentration >115 g/L and will be prepared to accept the risks [17].